Reimbursed Care Access in Martinique

Currently classified as a strictly controlled substance under French narcotics legislation with no authorised market marketing authorisation or reimbursed medical use outside clinical research. The French government and health agencies treat psilocybin as a listed stupéfiant; use, possession, manufacture and distribution are prohibited except when expressly authorised by the Agence nationale de sécurité du médicament et des produits de santé (ANSM) for authorised clinical trials. For example, the ANSM authorised a clinical trial titled “Psilocybine dans le trouble lié à l'usage de l'alcool avec dépression comorbide” (trial EU reference 2023-506647-42-00) and other trial applications have been submitted and evaluated under EU clinical trial regulation processes #. The national legal classification is recorded in the French lists of controlled substances established by arrêté (see French Public Health Code and related decrees), and parliamentary answers reiterate that psilocybin remains a scheduled narcotic and can only be used within properly authorised clinical trials or with an explicit ANSM authorisation. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is listed among narcotics in France and may only be used within authorised clinical trials or by specific experimental authorisations issued by ANSM under EU clinical-trial rules; no routine medical prescribing or public reimbursement exists. #.

Esketamine (Spravato®) is authorised in the European Union for treatment‑resistant depression and has undergone centralized EMA assessment; its EU product information describes restricted supervised use and monitoring requirements #. In France (and therefore in Martinique), the Haute Autorité de Santé (HAS) has evaluated SPRAVATO (eskétamine) and has issued opinions on its reimbursement status and conditions; HAS documents describe the clinical indication (adults with major depressive disorder resistant to at least two prior treatments, to be used in combination with an oral antidepressant) and the specific supervised administration requirements (clinic-based administration with monitoring for blood pressure and acute adverse effects) #.

Reimbursement and access specifics in France: HAS opinions and the subsequent listing decisions determine the conditions and rate of reimbursement by the French statutory health insurance (Sécurité sociale). HAS has issued favorable opinions for listing (with condition changes and updates over time) and maintains technical pages describing indications and the ASMR assessment that underpin reimbursement negotiations; following HAS opinion, price and reimbursement terms are negotiated at national level (CEPS) and SECU reimbursement applies when the product is listed. As an overseas department, Martinique follows the same national reimbursement and hospital/clinic certification framework — Spravato must be administered in certified healthcare settings, and patients eligible under the HAS/SEC U criteria can access reimbursed treatment per the national rules. For clinical and operational details (prescription restrictions, monitoring, administration under supervision), see the HAS SPRAVATO page and EMA product information. #; #.

Ketamine (chlorhydrate de kétamine) is a legally available medicinal product in France for anaesthesia and emergency uses and is widely used in hospital settings; it is also used in supervised clinical programmes and specialist psychiatric services for treatment‑resistant depression in off‑label applications where clinicians judge it appropriate. National drug-control law classifies hallucinogens and certain preparations as controlled, but the medical authorised uses (anaesthesia) and supervised off‑label uses in specialist centres are permitted under medical practice rules #.

Reimbursement and payer context: unlike esketamine (a licensed antidepressant product with a HAS assessment and negotiated reimbursement), generic ketamine preparations are not authorised or indicated as a marketed antidepressant product with a specific reimbursement pathway for depression. The use of ketamine for psychiatric indications in France is therefore generally considered off‑label clinical practice; reimbursement for off‑label uses depends on the healthcare setting: when administered in public hospitals or reimbursed hospital-care contexts (e.g., inpatient care, day hospital) costs may be covered under hospital funding and Sécurité sociale tariffs for the hospital stay/procedures, but there is no routine national reimbursement decision recognising ketamine as an approved antidepressant medication in the outpatient ambulatory market. Clinicians offering IV ketamine protocols for depression do so under medical responsibility, institutional protocols and in many cases within specialist centers or clinical research settings; patients should expect variability in coverage and potential out‑of‑pocket costs for ambulatory or private clinic administrations. For epidemiology, medical use and policy context see the OFDT synthesis. #.

Currently classified as a strictly controlled substance under French drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT is explicitly scheduled under French narcotics lists and plant/plant-preparation uses that contain DMT (for example ayahuasca) are also subject to control; access is limited to authorised clinical trials or exceptional ANSM-authorised research use. (French legal framework for hallucinogens and narcotics is summarised by OFDT). #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Like other synthetic tryptamines and classical psychedelics, 5‑MeO‑DMT falls within France’s strict narcotics framework and is only accessible under authorised clinical trials or exceptional ANSM approvals. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. France’s legal framework treats ibogaine (and Tabernanthe iboga derivatives) as prohibited or restricted; while historical use existed earlier in the 20th century, contemporary French law does not permit routine medical prescribing and any research use must be specifically authorised by ANSM. International reviews and national sources note ibogaine is outlawed or restricted in France. #; #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca preparations contain DMT, they fall under the same prohibitions as DMT itself; possession, importation or use is subject to narcotics control and only authorised in the context of an approved clinical trial or with express ANSM authorisation. Customs and public‑health enforcement follow national narcotics rules. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are controlled under French narcotics law (arrêté lists), and their use, possession and distribution are prohibited except under explicit research authorisations. #; #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family of substituted phenethylamines (2C‑X variants) are controlled under French narcotics legislation and are not authorised for clinical or therapeutic use except in the context of regulated research approved by ANSM. #.